Skip to main content
SpringerLink
Log in

Pharmacokinetics and Metabolism of the Plant Cannabinoids, Δ 9-Tetrahydrocannibinol, Cannabidiol and Cannabinol

  • Chapter
Cannabinoids

Part of the book series: Handbook of Experimental Pharmacology ((HEP,volume 168))

Abstract

Increasing interest in the biology, chemistry, pharmacology, and toxicology of cannabinoids and in the development of cannabinoid medications necessitates an understanding of cannabinoid pharmacokinetics and disposition into biological fluids and tissues. A drug’s pharmacokinetics determines the onset, magnitude, and duration of its pharmacodynamic effects. This review of cannabinoid pharmacokinetics encompasses absorption following diverse routes of administration and from different drug formulations, distribution of analytes throughout the body, metabolism by different tissues and organs, elimination from the body in the feces, urine, sweat, oral fluid, and hair, and how these processes change over time. Cannabinoid pharmacokinetic research has been especially challenging due to low analyte concentrations, rapid and extensive metabolism, and physicochemical characteristics that hinder the separation of drugs of interest from biological matrices—and from each other—and lower drug recovery due to adsorption of compounds of interest to multiple surfaces. Δ 9-Tetrahydrocannabinol, the primary psychoactive component of Cannabis sativa, and its metabolites 11-hydroxy-Δ 9-tetrahydrocannabinol and 11-nor-9-carboxy-tetrahydrocannabinol are the focus of this chapter, although cannabidiol and cannabinol, two other cannabinoids with an interesting array of activities, will also be reviewed. Additional material will be presented on the interpretation of cannabinoid concentrations in human biological tissues and fluids following controlled drug administration.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 629.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 799.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Adams IB, Martin BR (1996) Cannabis: pharmacology and toxicology in animals and humans. Addiction 91:1585–1614

    Article  PubMed  CAS  Google Scholar 

  • Agurell S, Leander K (1971) Stability, transfer and absorption of cannabinoid constituents of cannabis (hashish) during smoking. Acta Pharm Suec 8:391–402

    PubMed  CAS  Google Scholar 

  • Agurell S, Gillespie H, Halldin M, Hollister LE, Johansson E, Lindgren JE, Ohlsson A, Szirmai M, Widman M (1984) A review of recent studies on the pharmacokinetics and metabolism of delta-1-tetrahydrocannabinol, cannabidiol and cannabinol in man. In: Paton SW, Nahas GG (eds) Marijuana’ 84. IRL Press, Oxford, pp 49–62

    Google Scholar 

  • Agurell S, Halldin M, Lindgren JE, Ohlsson A, Widman M, Gillespie H, Hollister L (1986) Pharmacokinetics and metabolism of delta-tetrahydrocannabinol and other cannabinoids with emphasis on man. Pharmacol Rev 38:21–43

    PubMed  CAS  Google Scholar 

  • Atkinson HC, Begg EJ, Darrlow BA (1988) Drugs in human milk clinical pharmacokinetic considerations. Clin Pharmacokinet 14:217–240

    PubMed  CAS  Google Scholar 

  • Azorlosa JL, Heishman SJ, Stitzer ML, Mahaffey JM (1992) Marijuana smoking: effect of varying delta 9-tetrahydrocannabinol content and number of puffs. J Pharmacol Exp Ther 261:114–122

    PubMed  CAS  Google Scholar 

  • Bailey JR, Cunny HC, Paule M, Slikker W Jr (1987) Fetal disposition of delta-9-tetrahydrocannbinol (THC) during late pregnancy in the rhesus monkey. Toxicol Appl Pharmacol 90:315–321

    Article  PubMed  CAS  Google Scholar 

  • Baker D, Pryce G, Croxford JL, Brown P, Pertwee RG, Huffman JW, Layward L (2000) Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature 404:84–87

    Article  PubMed  CAS  Google Scholar 

  • Balabanova S, Schneider E (1989) Nachweis von drogen im schweis. Beitr Gerichtl Med 48:45–49

    Google Scholar 

  • Ben-Zvi Z, Burstein S (1974) 7-Oxo-delta-1-tetrahydrocannabinol: a novel metabolite of delta 1 tetrahydrocannabinol. Int J Clin Pharmacol Ther 8:223–229

    CAS  Google Scholar 

  • Ben-Zvi Z, Bergen JR, Burstein S, Sehgal PK, Varanelli C (1976)The metabolism of deltatetrahydrocannabinol in the rhesus monkey. In: Braude MC, Szara S (eds) The pharmacology of marijuana. Raven Press, New York, pp 63–75

    Google Scholar 

  • Benowitz NL, Nguyen TL, Jones RT, Herning RI, Bachman J (1980) Metabolic and psychophysiologic studies of cannabidiol-hexobarbital interaction. Clin Pharmacol Ther 28:115–117

    Article  PubMed  CAS  Google Scholar 

  • Binitie A (1975) Psychosis following ingestion of hemp in children. Psychopharmacologia 44:301–302

    Article  PubMed  CAS  Google Scholar 

  • Blackard C, Tennes K (1984) Human placental transfer of cannabinoids. N Engl J Med 311:797

    PubMed  CAS  Google Scholar 

  • Blanc JA, Manneh VA, Ernst R, Berger DE, de Keczer SA, Chase C, Centofanti JM, DeLizza AJ (1993) Adsorption losses from urine-bases cannabinoid calibrators during routine use. Clin Chem 39:1705–1717

    PubMed  CAS  Google Scholar 

  • Bloom AS (1982) Effect of delta-9-tetrahydrocannabinol on the synthesis of dopamine and norepinephrine in mouse brain synaptosomes. J Pharmacol Exp Ther 221:97–103

    PubMed  CAS  Google Scholar 

  • Bornheim LM, Lasker JM, Raucy JL (1992) Human hepatic microsomal metabolism of delta-1-tetrahydrocannabinol. Drug Metab Dispos 20:241–246

    PubMed  CAS  Google Scholar 

  • Brenneisen R, Egli A, ElSohly MA, Henn V, Spiess Y (1996) The effect of orally and rectally administered delta-9-tetrahydrocannabinol on spasticity: a pilot study with 2 patients. Int J Clin Pharmacol Ther 34:446–452

    PubMed  CAS  Google Scholar 

  • Burstein S, Rosenfeld J, Wittstruck T (1972) Isolation and characterization of two major urinary metabolites of delta-1-tetrahydrocannabinol. Science 176:422–424

    PubMed  CAS  Google Scholar 

  • Cairns ER, Howard RC, Hung CT, Menkes DB (1990) Saliva THC levels and cannabis intoxication. Report No. 2411, Chemistry Division, Division of Scientific and Industrial Research, Lower Hutt, New Zealand, pp 1–71

    Google Scholar 

  • Cairns T, Kippenberger DJ, Scholtz H, Baumgartner WA (1995) determination of carboxy-THC in hair by mass spectrometry/mass spectrometry. In: de Zeeuw RA, Al Hosani I, Al Munthiri S, Maqbool A (eds) Hair Analysis in Forensic Toxicology: proceedings of the 1995 international conference and workshop. The Organizing Committee of the conference, Abu Dhabi, pp 185–193

    Google Scholar 

  • Cami J, Guerra D, Ugena B, Segura J, de La Torre R (1991) Effect of subject expectancy on the THC intoxication and disposition from smoked hashish cigarettes. Pharmacol Biochem Behav 40:115–119

    PubMed  CAS  Google Scholar 

  • Chiang CN, Rapaka RS (1987) Pharmacokinetics and disposition of cannabinoids. In: Rapaka RS, Makriyannis A (eds) NIDA research monograph—structure-activity relationships of the cannabinoids. National Institute on Drug Abuse, Rockville, pp 173–188

    Google Scholar 

  • Christophersen AS (1986) TetraHydroCannabinol stability in whole blood: plastic versus glass containers. J Anal Toxicol 10:129–131

    PubMed  CAS  Google Scholar 

  • Cirimele V (1996) Cannabis and amphetamine determination in human hair. In: Kintz P (ed) Drug testing in hair. CRC Press, Boca Raton, pp 181–189

    Google Scholar 

  • Cirimele V, Sachs H, Kintz P, Mangin P (1996) Testing human hair for cannabis. III. Rapid screening procedure for the simultaneous identification of delta9-tetrahydrocannabinol, cannabinol, and cannabidiol. J Anal Toxicol 20:13–16

    PubMed  CAS  Google Scholar 

  • Claussen U, Korte F (1968) Uber das verhalten von hanf und von delta-9-6a, 10a-trans-tetrahydrocannabinol biem rauchen. Justus Liebigs Ann Chem 713:162–165

    PubMed  CAS  Google Scholar 

  • Cone EJ, Lange R, Darwin WD (1998) In vivo adulteration: excess fluid ingestion causes false-negative marijuana and cocaine urine test results. J Anal Toxicol 22:460–473

    PubMed  CAS  Google Scholar 

  • Dewey WL, McMillan DE, Harris LS, Turk RF (1972) Distribution of radioactivity in brain of tolerant and nontolerant pigeons treated with 3-H-delta-9-tetrahydrocannabinol. Biochem Pharmacol 22:399–405

    Google Scholar 

  • Ehorn C, Fretthold D, Maharaj M (1994) Ion trap GC/MS/MS for analysis of THC from sweat. Abstract presented at the Society of Forensic Toxicologists annual meeting, Tampa, 31 October-4 November, p 11

    Google Scholar 

  • Ellis GM, Mann MA, Judson BA, Schramm NT, Tashchian A (1985) Excretion patterns of cannabinoid metabolites after last use in a group of chronic users. Clin Pharmacol Ther 38:572–578

    Article  PubMed  CAS  Google Scholar 

  • ElSohly HN, Boeren EG, Turner CE, ElSohly MA (1984) Constituents of cannabis sativa L. XXIV: Cannabitetrol, a new polyhydroxylated cannabinoid. In: Agurell S, Dewey WL, Willette RE (eds) The cannabinoids: chemical, pharmacologic and therapeutic aspects. Academic Press, Orlando, pp 89–96

    Google Scholar 

  • Feng S, ElSohly MA, Salamone S, Salem MY (2000) Simultaneous analysis of delta-9-THC and its major metabolites in urine, plasma, and meconium by GC-MS using an immunoafffinity extraction procedure. J Anal Toxicol 24:395–402

    PubMed  CAS  Google Scholar 

  • Foltz RL (1984) Analysis of cannabinoids in physiological specimens by gas chromatography/ mass spectrometry. In: Baselt RC (ed) Advances in analytical toxicology. Biomedical Publications, Foster City, pp 125–157

    Google Scholar 

  • Garrett ER, Hunt CA (1974) Physiochemical properties, solubility, and protein binding of delta-9-tetrahydrocannabinol. J Pharm Pharm Sci 63:1056–1064

    CAS  Google Scholar 

  • Garrett ER, Hunt CA (1977) Pharmacokinetics of delta-9-tetrahydrocannabinol in dogs. J Pharm Pharm Sci 66:395–406

    CAS  Google Scholar 

  • Gjerde H, Beylich KM, Morland J (1993) Incidence of alcohol and drugs in fatally injured car drivers in Norway. Accid Anal Prev 25:479–483

    Article  PubMed  CAS  Google Scholar 

  • Green MD, Belanger G, Hum DW, Belanger A, Tephly TR (1997) Glucuronidation of opioids, carboxylic acid-containing drugs, and hydroxylated xenobiotics catalyzed by expressed monkey UDP-glucuronosyltransferase 2B9 protein. Drug Metab Dispos 25:1389–1394

    PubMed  CAS  Google Scholar 

  • Greene ML, Saunders DR (1974) Metabolism of tetrahydrocannabinol by the small intestine. Gastroenterology 66:365–372

    PubMed  CAS  Google Scholar 

  • Gross SJ, Soares JR (1978) Validated direct blood delta-9-THC radioimmune quantitation. J Anal Toxicol 2:98–100

    CAS  Google Scholar 

  • Gross SJ, Worthy TE, Nerder L, Zimmermann EG, Soares JR, Lomax P (1985) Detection of recent cannabis use by saliva delta-9-THC radioimmunoassay. J Anal Toxicol 9:1–5

    PubMed  CAS  Google Scholar 

  • Grotenhermen F (2003) Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet 42:327–360

    PubMed  CAS  Google Scholar 

  • Gustafson RA, Moolchan ET, Barnes A, Levine B, Huestis MA (2003) Validated method for the simultaneous determination of delta-9-tetrahydrocannabinol (THC), 11-hydroxy-THC and 11-nor-9-carboxy-THC in human plasma using solid phase extraction and gas chromatography-mass spectrometry with positive chemical ionization. J Chromatogr B Analyt Technol Biomed Life Sci 798:145–154

    PubMed  CAS  Google Scholar 

  • Guy GW, Robson PJ (2004a) A phase I, double blind, three-way crossover study to assess the pharmacokinetic profile of cannabis basedmedicine extract (CBME) administered sublingually in variant cannabinoid ratios in normal healthy male volunteers (GWPK0215). J Cannabis Ther 3:121–152

    Google Scholar 

  • Guy GW, Robson PJ (2004b) A phase I, open label, four-way crossover study to compare the pharmacokinetic profiles of a single dose of 20 mg of a cannabis basedmedicine extract (CBME) administered on 3 different areas of the buccal mucosa and to investigate the pharmacokinetics of CBME per oral in healthy male and female volunteers (GWPK0112). J Cannabis Ther 3:79–120

    Google Scholar 

  • Hall BJ, Satterfield-Doerr M, Parikh AR, Brodbelt JS (1998) Determination of cannabinoids in water and human saliva by solid-phase microextraction and quadrupole ion trap gas chromatography-mass spectrometry. Anal Chem 70:1788–1796

    Article  PubMed  CAS  Google Scholar 

  • Halldin MM, Widman M, Bahr CV, Lindgren JE, Martin BR (1982) Identification of in vitro metabolites of delta-tetrahydrocannabinol formed by human livers. Drug Metab Dispos 10:297–301

    PubMed  CAS  Google Scholar 

  • Hampson AJ, Grimaldi M, Axelrod J, Wink D (1998) Cannabidiol and (—) delta-9-tetrahydrocannabinol are neuroprotective antioxidants. Proc Natl Acad Sci U S A 95:8268–8273

    Article  PubMed  CAS  Google Scholar 

  • Hanson VW, Buonarati MH, Baselt RC, Wade NA, Yep C, Biasotti AA, Reeve VC, Wong AS, Orbanowsky MW (1983) Comparison of 3H-and 125I-radioimmunoassay and gas chromatography/ mass spectrometry for the determination of delta-9-tetrahydrocannabinol and cannabinoids in blood and serum. J Anal Toxicol 7:96–102

    PubMed  CAS  Google Scholar 

  • Harder S, Rietbrock S (1997) Concentration-effect relationship of delta-9-tetrahydrocannabiol and prediction of psychotropic effects after smoking marijuana. Int J Clin Pharmacol Ther 35:155–159

    PubMed  CAS  Google Scholar 

  • Harvey DJ (2001) Absorption, distribution, and biotransformation of the cannabinoids. In: Nahas GG, Sutin KM, Harvey DJ, Agurell S (eds) Marijuana and medicine. Humana Press, Totowa, pp 91–103

    Google Scholar 

  • Harvey DJ, Mechoulam R (1990) Metabolites of cannabidiol identified in human urine. Xenobiotica 20:303–320

    PubMed  CAS  Google Scholar 

  • Harvey DJ, Paton WDM (1986) Metabolism of the cannabinoids. Rev Biochem Toxicol 6:221–264

    Google Scholar 

  • Harvey DJ, Martin BR, Paton WDM (1979) Identification and measurement of cannabinoids and their in vivo metabolites in liver by gas chromatography-mass spectrometry. In: Nahas GG, Paton WDM (eds) Marijuana: biological effects. Pergamon Press, Oxford, pp 45–62

    Google Scholar 

  • Hawks RL (1982) The constituents of cannabis and the disposition and metabolism of cannabinoids. In: Hawks R (ed) The analysis of cannabinoids in biological Fluids. Research Monograph 42. National Institute on Drug Abuse, Rockville, pp 125–137

    Google Scholar 

  • Hawks RL (1983) Developments in cannabinoid analyses of body fluids: implications for forensic applications. In: Agurell S, Dewey W, Willette R (eds) The cannabinoids: chemical, pharmacologic, and therapeutic aspects. Academic Press, Rockville, pp 1–12

    Google Scholar 

  • Heishman SJ, Stitzer ML, Yingling JE (1989) Effects of tetrahydrocannabinol content on marijuana smoking behavior, subjective reports, and performance. Pharmacol Biochem Behav 34:173–179

    Article  PubMed  CAS  Google Scholar 

  • Holdcroft A (1984) Pain therapy. In: Grotenhermen F, Russo E (eds) Cannabis and cannabinoids. Pharmacology, toxicology, and therapeutic potential. The Haworth Integrative Healing Press, New York, pp 181–186

    Google Scholar 

  • Huang W, Moody DE, Andrenyak DM, Smith EK, Foltz RL, Huestis MA, Newton JF (2001) Simultaneous determination of delta-9-tetrahydrocannabinol and 11-nor-9-carboxydelta-9-tetrahydrocannabinol in human plasma by solid phase extraction and gas chromatography—negative ionchemical ionization—massspectrometry. J Anal Toxicol 25:531–537

    PubMed  CAS  Google Scholar 

  • Huestis MA, Cone EJ (1998a) Alternative testing matrices. In: Karch SB (ed) Drug abuse handbook. CRC Press, Boca Raton, pp 799–857

    Google Scholar 

  • Huestis MA, Cone EJ (1998b) Differentiating new marijuana use from residual drug excretion in occasional marijuana users. J Anal Toxicol 22:445–454

    PubMed  CAS  Google Scholar 

  • Huestis MA, Cone EJ (2004) Relationship of Delta-9-tetrahydrocannabinol concentrations in oral fluid and plasma after controlled administration of smoked cannabis. J Anal Toxicol 28:394–399

    PubMed  CAS  Google Scholar 

  • Huestis MA, Dickerson S, Cone EJ (1992a) Can saliva THC levels be correlated to behavior? American Academy of Forensic Sciences Annual Meeting, New Orleans, p 190

    Google Scholar 

  • Huestis MA, Henningfield JE, Cone EJ (1992b) Blood cannabinoids. I. Absorption of THC and formation of 11-OH-THC and THCCOOH during and after smoking marijuana. J Anal Toxicol 16:276–282

    PubMed  CAS  Google Scholar 

  • Huestis MA, Henningfield JE, Cone EJ (1992c) Blood cannabinoids. II.Models for the prediction of time of marijuana exposure from plasma concentrations of delta-9-tetrahydrocannabinol (THC) and 11-nor-9-carboxy-delta-9-tetrahydrocannabinol (THCCOOH). J Anal Toxicol 16:283–290

    PubMed  CAS  Google Scholar 

  • Huestis MA, Sampson AH, Holicky BJ, Henningfield JE, Cone EJ (1992d) Characterization of the absorption phase of marijuana smoking. Clin Pharmacol Ther 52:31–41

    Article  PubMed  CAS  Google Scholar 

  • Huestis MA, Mitchell JM, Cone EJ (1995) Detection times of marijuana metabolites in urine by immunoassay and GC-MS. J Anal Toxicol 19:443–449

    PubMed  CAS  Google Scholar 

  • Huestis MA, Mitchell JM, Cone EJ (1996) Urinary excretion profiles of 11-nor-9-carboxy-Δ9-tetrahydrocannabinol in humans after single smoked doses of marijuana. J Anal Toxicol 20:441–452

    PubMed  CAS  Google Scholar 

  • Hunt CA, Jones RT (1980) Tolerance and disposition of tetrahydrocannabinol in man. J Pharmacol Exp Ther 215:35–44

    PubMed  CAS  Google Scholar 

  • Hunt CA, Jones RT, Herning RI, Bachman J (1981) Evidence that cannabidiol does not significantly alter the pharmacokinetics of tetrahydrocannabinol in man. J Pharmacokinet Biopharm 9:245–260

    Article  PubMed  CAS  Google Scholar 

  • Iribarne C, Berthou F, Baird S, Dreano Y, Picart D, Bail JP, Beaune P, Menez JF (1996) Involvement of cytochrome P450 3A4 enzyme in the N-demethylation of methadone in human liver microsomes. Chem Res Toxicol 9:365–373

    Article  PubMed  CAS  Google Scholar 

  • Jehanli A, Brannan S, Moore L, Spiehler VR (2001) Blind trials of an onsite saliva drug test for marijuana and opiates. J Forensic Sci 46:1214–1220

    PubMed  CAS  Google Scholar 

  • Joern WA (1992) Surface adsorption of the urinary marijuana carboxy metabolite: the problem and a partial solution. J Anal Toxicol 16:401

    PubMed  CAS  Google Scholar 

  • Johansson E, Halldin MM (1989) Urinary excretion half-life of delta1-tetrahydrocannabinol-7-oic acid in heavy marijuana users after smoking. J Anal Toxicol 13:218–223

    PubMed  CAS  Google Scholar 

  • Johansson E, Agurell S, Hollister LE, Halldin MM (1988) Prolonged apparent half-life of delta-1-tetrahydrocannabinol in plasma of chronic marijuana users. J PharmPharmacol 40:374–375

    CAS  Google Scholar 

  • Johansson E, Halldin MM, Agurell S, Hollister LE, Gillespie HK (1989a) Terminal elimination plasma half-life of delta-1-tetrahydrocannabinol (selta-1-THC) in heavy users of marijuana. Eur J Clin Pharmacol 37:273–277

    PubMed  CAS  Google Scholar 

  • Johansson E, Noren K, Sjovall J, Halldin MM (1989b) Determination of delta-1-tetrahydrocannabinol in human fat biopsies from marihuana users by gas chromatography-mass spectrometry. Biomed Chromatogr 3:35–38

    Article  PubMed  CAS  Google Scholar 

  • Karst M, Salim K, Burstein S, Conrad I, Hoy L, Schneider U (2003) Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain. J Am Med Assoc 290:1757–1762

    Article  CAS  Google Scholar 

  • Kelly P, Jones RT (1992) Metabolism of tetrahydrocannabinol in frequent and infrequent marijuana users. J Anal Toxicol 16:228–235

    PubMed  CAS  Google Scholar 

  • Kemp PM, Abukhalaf IK, Manno JE, Manno BR, Alford DD, Abusada GA (1995a) Cannabinoids in humans. I. Analysis of delta-9-tetrahydrocannabinol and six metabolites in plasma and urine using GC-MS. J Anal Toxicol 19:285–291

    PubMed  CAS  Google Scholar 

  • Kemp PM, Abukhalaf IK, Manno JE, Manno BR, Alford DD, McWilliams ME, Nixon FE, Fitzgerald MJ, Reeves RR, Wood MJ (1995b) Cannabinoids in humans. II. The in.uence of three methods of hydrolysis on the concentration of THC and two metabolites in urine. J Anal Toxicol 19:292–298

    PubMed  CAS  Google Scholar 

  • Kidwell DA, Holland JC, Athanaselis S (1998) Testing for drugs of abuse in saliva and sweat. J Chromatogr 713:111–135

    CAS  Google Scholar 

  • Kim KR, Yoon HR (1996) Rapid screening for acidic non-steroidal anti-inflammatory drugs in urine by gas chromatography-mass spectrometry in the selected-ion monitoring mode. J Chromatogr B Biomed Appl 682:55–66

    PubMed  CAS  Google Scholar 

  • Kintz P, Cirimele V, Mangin P (1995) Testing human hair for cannabis II. Identifcation of THC-COOH by GC-MS-NCI as a unique proof. J Forensic Sci 40:619–622

    PubMed  CAS  Google Scholar 

  • Kintz P, Brenniesen R, Bundeli P, Mangin P (1997) Sweat testing for heroin and metabolites in a heroin maintenance program. Clin Chem 43:736–739

    PubMed  CAS  Google Scholar 

  • Kintz P, Cirimele V, Ludes B (2000) Detection of cannabis in oral fluid (saliva) and forehead wipes (sweat) from impaired drivers. J Anal Toxicol 24:557–561

    PubMed  CAS  Google Scholar 

  • Kreuz DS, Axelrod J (1973) Delta-9-tetrahydrocannabinol: localization in body fat. Science 179:391–393

    PubMed  CAS  Google Scholar 

  • Krishna DR, Klotz U (1994) Extrahepatic metabolism of drugs in humans. Clin Pharmacokinet 26:144–160

    Article  PubMed  CAS  Google Scholar 

  • Law B, Mason PA, Moffat AC, Gleadle RI, King LJ (1984) Forensic aspects of the metabolism and excretion of cannabinoids following oral ingestion of cannabis resin. J Pharm Pharmacol 36:289–294

    PubMed  CAS  Google Scholar 

  • Lee CC, Chiang CN (1985) Appendix.Maternal-fetal transfer of abused substances: pharmacokinetic and pharmacodynamic data. In: Chiang CN, Lee CC (eds) NIDA Research monograph 60. U.S. Department of Health and Human Services, Rockville, pp 110–147

    Google Scholar 

  • Lemberger L, Silberstein SD, Axelrod J, Kopin IJ (1970) Marihuana: studies on the disposition and metabolism of delta-9-tetrahydrocannabinol in man. Science 170:1320–1322

    PubMed  CAS  Google Scholar 

  • Lemberger L, Tamarkin NR, Axelrod J (1971) Delta-9-tetrahydrocannabinol: metabolism and disposition in long-term marihuana smokers. Science 173:72–74

    PubMed  CAS  Google Scholar 

  • Lemberger L, Crabtree RE, Rowe HM (1972) 11-hydroxy-delta-9-tetrahydrocannabinol: pharmacology, disposition, and metabolism of a major metabolite of marijuana in man. Science 177:62–64

    PubMed  CAS  Google Scholar 

  • Lindgren JE, Ohlsson A, Agurell S, Hollister L, Gillespie H (1981) Clinical effects and plasma levels of delta-9-tetrahydrocannabinol (delta-9-THC) in heavy and light users of cannabis. Psychopharmacology (Berl) 74:208–212

    Article  PubMed  CAS  Google Scholar 

  • Malfait AM, Galllily R, Sumariwalla PF, Malik AS, Andreakos E, Mechoulam R, Feldmann M (2000) The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic inmurine collagen-induced arthritis. Proc Natl Acad Sci U S A 97:9561–9566

    Article  PubMed  CAS  Google Scholar 

  • Manno JE, Ferslew KE, Manno BR (1984) Urine excretion patterns of cannabinoids and the clinical application of the EMIT-d.a.u. cannabinoid urine assay for substance abuse treatment. In: Agurell S, Dewey WL, Willette RE (eds) The cannabinoids: chemical, pharmacologic, and therapeutic aspects. Harcourt Brace Jonanovich, Orlando, pp 281–290

    Google Scholar 

  • Manno JE, Manno BR, Kemp PM, Alford DD, Abukhalaf IK, McWilliams ME, Hagaman FN, Fitzgerald MJ (2001) Temporal indication of marijuana use can be estimated from plasma and urine concentrations of delta-9-tetrahydrocannabinol, 11-hydroxy-delta-9-tetrahydrocannabinol, and 11-nor-delta-9-tetrahydrocannabinol-9-carboxylic acid. J Anal Toxicol 25:538–549

    PubMed  CAS  Google Scholar 

  • Martin BR, Dewey WL, Harris LS, Beckner JS (1977) 3H-Delta-9-tetrahydrocannbinol distribution in pregnant dogs and their fetuses. Res Commun Chem Pathol Pharmacol 17:457–470

    PubMed  CAS  Google Scholar 

  • Mason AP, McBay AJ (1984) Ethanol, marijuana, and other drug use in 600 drivers killed in single-vehicle crashers in North Carolina, 1978–1981. J Forensic Sci 29:987–1026

    PubMed  CAS  Google Scholar 

  • Mason AP, McBay AJ (1985) Cannabis: pharmacology and interpretation of effects. J Forensic Sci 30:615–631

    PubMed  CAS  Google Scholar 

  • Matsunaga T, Iwawaki Y, Watanabe K, Yamamoto I, Kageyama T, Yoshimura H (1995) Metabolism of delta-9-tetrahydrocannabinol by cytochrome P450 isozymes purified from hepatic microsomes of monkeys. Life Sci 56:2089–2095

    Article  PubMed  CAS  Google Scholar 

  • Mattes RD, Shaw LM, Edling-Owens J, Engelman K, ElSohly MA (1993) Bypassing the first-pass effect for the therapeutic use of cannabinoids. Pharmacol Biochem Behav 44:745–747

    Article  PubMed  CAS  Google Scholar 

  • Mattes RD, Engelman K, Shaw LM, ElSohly MA (1994) Cannabinoids and appetite stimulation. Pharmacol Biochem Behav 49:187–195

    Article  PubMed  CAS  Google Scholar 

  • McArdle K, Mackie P, Pertwee R, Guy G, Whittle B, Hawksworth G (2001) Selective inhibition of delta-9-tetrahydrocannabinol metabolite formation by cannabidiol in vitro (abstract) in Proceedings of the BTS Annual Congress. Toxicology 168:133–134

    Google Scholar 

  • McBurney LJ, Bobbie BA, Sepp LA (1986) GC/MS and Emit analyses for delta-9-tetrahydrocannabinol metabolites in plasma and urine of human subjects. J Anal Toxicol 10:56–64

    PubMed  CAS  Google Scholar 

  • Mechoulam R (1970) Marihuana chemistry. Science 168:1159–1166

    PubMed  CAS  Google Scholar 

  • Mechoulam R, Zvi ZB, Agurell S, Nilsson IM, Nilsson JLG, Edery H, Grunfeld Y (1973) Delta-6 tetrahydrocannabinol-7-oic acid, a urinary delta-6-THC metabolite: isolation and synthesis. Experientia 29:1193–1195

    Article  PubMed  CAS  Google Scholar 

  • Meier HJ, Vonesch HJ (1997) Cannabis-intoxikationnach salatgenuss. Schweiz Med Wochenschr 127:214–218

    PubMed  CAS  Google Scholar 

  • Melamede R (1984) Possible mechanisms in autoimmune diseases. In: Grotenhermen F, Russo E (eds) Cannabis and cannabinoids. Pharmacology, toxicology, and therapeutic potential. The Haworth Integrative Healing Press, New York, pp 111–122

    Google Scholar 

  • Moeller MR, Doerr G, Warth S (1992) Simultaneous quantitation of delta-9-tetrahydrocannabinol (THC) and 11-nor-9-carboxy-delta-9-tetrahydrocannabinol (THC-COOH) in serumby GC/MS using deuterated internal standards and its application to a smoking study and forensic cases. J Forensic Sci 37:969–983

    PubMed  CAS  Google Scholar 

  • Moore C, Guzaldo F, Donahue T (2001) The determination of 11-nor-delta-9-tetrahydrocannabinol-9-carboxylic acid (THC-COOH) in hair using negative ion gas chromatographymass spectrometry and high-volume injection. J Anal Toxicol 25:555–558

    PubMed  CAS  Google Scholar 

  • Mura P, Kintz P, Papet Y, Ruesch G, Piriou A (1999) Evaluation of six rapid tests for screening of cannabinoids in sweat, saliva and urine. Acta Clin Belg 1:35–38

    CAS  Google Scholar 

  • Nebro W, Barnes A, Gustafson R, Moolchan E, Huestis M (2004) Delta-9-tetrahydrocannabinol (THC), 11-hydroxy-delta-9-tetrahydrocannabinol (11-OH-THC) and 11-nor-9-carboxy-delta-9-tetrahydrocannabinol (THCCOOH) in human plasma following oral administration of hemp oil. 2004 FBI/SOFT/TIAFT Meeting

    Google Scholar 

  • Niedbala RS, Kardos KW, Fritch DF, Kardos S, Fries T, Waga J (2001) Detection of marijuana use by oral fluid and urine analysis following single-dose administration of smoked and oral marijuana. J Anal Toxicol 25:289-303

    Google Scholar 

  • Ohlsson A, Lindgren JE, Wahlen A, Agurell S, Hollister LE, Gillespie HK (1980) Plasma delta-9-tetrahydrocannabinol concentrations and clinical effects after oral and intravenous administration and smoking. Clin Pharmacol Ther 28:409–416

    Article  PubMed  CAS  Google Scholar 

  • Ohlsson A, Lindgren JE, Wahlen A, Agurell S, Hollister LE, Gillespie HK (1981) Plasma levels of delta-9-tetrahydrocannabinol after intravenous, oral and smoke administration. NIDA Res Monogr 34:250–256

    PubMed  CAS  Google Scholar 

  • Ohlsson A, Lindgren JE, Wahlen A, Agurell S, Hollister LE, Gillespie HK (1982) Single dose kinetics of deuterium-labelled delta-1-tetrahydrocannabinol in heavy and light cannabis users. Biomed Environ Mass Spectrom 9:6–10

    Article  CAS  Google Scholar 

  • Ohlsson A, Agurell S, Londgren JE, Gillespie HK, Hollister LE (1985) Pharmacokinetic studies of delta-1-tetrahydrocannabinol in man. In: Barnett G, Chiang CN (eds) Pharmacokinetics and pharmacodynamics of psychoactive drugs. Mosby Yearbook, St Louis, pp 75–92

    Google Scholar 

  • Ohlsson A, Lindgren JE, Andersson S, Agurell S, Gillespie H, Hollister LE (1986) Single-dose kinetics of deuterium-labelled cannabidiol in man after smoking and intravenous administration. Biomed Environ Mass Spectrom 13:77–83

    Article  PubMed  CAS  Google Scholar 

  • Owens SM, McBay AJ, Reisner HM, Perez-Reyes M (1981) 125 l radioimmunoassay of delta-9-tetrahydrocannabinol in blood and plasma with a solid-phase second-antibody separation method. Clin Chem 27:619–624

    PubMed  CAS  Google Scholar 

  • Peat MA (1989) Distribution of delta-9-tetrahydrocannabinol and its metabolites. In: Baselt RC (ed) Advances in analytical toxicology II. Year Book Medical Publishers, Chicago, pp 186–217

    Google Scholar 

  • Peel HW, Perrigo BJ, Mikhael NZ (1984) Detection of drugs in saliva of impaired drivers. J Forensic Sci 29:185–189

    PubMed  CAS  Google Scholar 

  • Perez-Reyes M (1985) Pharmacodynamics of certain drugs of abuse. In: Barnett G, Chiang CN (eds) Pharmacokinetics and pharmacodynamics of psychoactive drugs. Biomedical Publications, Foster City, pp 287–310

    Google Scholar 

  • Perez-Reyes M (1990) Marijuana smoking: factors that influence the bioavailability of tetrahydrocannabinol. In: Chiang CN, Hawks RL (eds) Research findings on smoking of abused substances. NIDA Research Monograph 99, Rockville, pp 42–62

    Google Scholar 

  • Perez-Reyes M, Wall ME (1982) Presence of delta-9-tetrahydrocannabinol in human milk. N Engl J Med 307:819–820

    PubMed  CAS  Google Scholar 

  • Perez-Reyes M, Timmons MC, Lipton MA, Davis KH, Wall ME (1972) Intravenous injection in man of delta-9-tetrahydrocannabinol and 11-OH-delta-9-tetrahydrocannabinol. Science 177:633–635

    PubMed  CAS  Google Scholar 

  • Perez-Reyes M, Lipton MA, Timmons MC, Wall ME, Brine DR, Davis KH (1973a) Pharmacology of orally administered delta-9-tetrahydrocannabinol. Clin Pharmacol Ther 14:48–55

    PubMed  CAS  Google Scholar 

  • Perez-Reyes M, Timmons MC, Davis KH, Wall EM (1973b) A comparison of the pharmacological activity in man of intravenously administered delta-9-tetrahydrocannabinol, cannabinol and cannabidiol. Experientia 29:1368–1369

    Article  PubMed  CAS  Google Scholar 

  • Perez-Reyes M, Owens SM, Di Guiseppi S (1981) The clinical pharmacology and dynamics of marijuana cigarette smoking. J Clin Pharmacol 21:201S–207S

    PubMed  CAS  Google Scholar 

  • Perez-Reyes M, Di Guiseppi S, Davis KH, Schindler VH, Cook CE (1982) Comparison of effects of marijuana cigarettes of three different potencies. Clin Pharmacol Ther 31:617–624

    Article  PubMed  CAS  Google Scholar 

  • Pertwee RG (2004) The pharmacology and therapeutic potential of cannabidiol. In: Di Marzo V (ed) Cannabinoids. Kluwer Academic/Plenum Publishers, New York, pp 32–83

    Google Scholar 

  • Plasse T (1984) Antiemetic effects of cannabinoids. In: Grotenhermen F, Russo E (eds) Cannabis and cannabinoids. Pharmacology, toxicology, and therapeutic potential. The Haworth Integrative Healing Press, New York, pp 165–180

    Google Scholar 

  • Samyn N, van Haeren C (2000) On-site testing of saliva and sweat with Drugwipe and determination of concentrations of drugs of abuse in saliva, plasma and urine of suspected users. Int J Legal Med 113:150–154

    Article  PubMed  CAS  Google Scholar 

  • Shaw LM, Edling-Owens J, Mattes R (1991) Ultrasensitive measurement of delta-9-tetrahydrocannabinol with a high energy dynode detector and electron-capture negative chemical-ionization mass spectrometry. Clin Chem 37:2062–2068

    PubMed  CAS  Google Scholar 

  • Soares JR, Gross SJ (1976) Separate radioimmune measurements of body fluid delta-9THC and 11-nor-9-carboxy-delta-THC. Life Sci 19:1711–1717

    Article  PubMed  CAS  Google Scholar 

  • Soares JR, Grant JD, Gross SJ (1982) Significant developments in radioimmune methods applied to delta-9-THC and its 9-substitutedmetabolites. In: Hawks R (ed) NIDA Research Monograph 42: National Institute on Drug Abuse, Bethesda, pp 44–55

    Google Scholar 

  • Sporkert F, Pragst F, Ploner CJ, Tschirch A, Stadelmann AM (2001) Pharmacokinetic investigations and delta-9-tetrahydrocannabinol and its metabolites after single administration of 10 mg Marinol in attendance of a psychiatric study. The Annual Meeting of The International Association of Forensic Toxicologists, Prague, pp 1–62

    Google Scholar 

  • Stinchcomb AL, Valiveti S, Hammell DC, Ramsey DR (2004) Human skin permeation of delta-8-tetrahydrocannabinol, cannabidiol and cannabinol. J Pharm Pharmacol 56:291–297

    Article  PubMed  CAS  Google Scholar 

  • Turner CE, ElSohly MA, Boeren EG (1980) Constituents of cannabis sativa L. XVII. A review of the natural constituents. J Nat Prod 43:169–234

    Article  PubMed  CAS  Google Scholar 

  • Vaughan CW, Christie MJ (1984) Mechanisms of cannabinoid analgesia. In: Grotenhermen F, Russo E (eds) Cannabis and cannabinoids. Pharmacology, toxicology, and therapeutic potential. The Haworth Integrative Healing Press, New York, pp 89–100

    Google Scholar 

  • Wall ME, Perez-Reyes M (1981) The metabolism of delta-9-tetrahydrocannabinol and related cannabinoids in man. J Clin Pharmacol 21:178S–189S

    PubMed  CAS  Google Scholar 

  • Wall ME, Taylor HL (1984) Conjugation of acidic metabolites of delta-8 and delta-9-THC in man. In: Harvey DJ, Paton SW, Nahas GG (eds) Marihuana 84 Proceedings of the Oxford Symposium on Cannabis. IRL Press Limited, Oxford, pp 69–76

    Google Scholar 

  • Wall ME, Brine DR, Perez-Reyes M (1976) Metabolism of cannabinoids in man. In: Braude MC, Szara S (eds) The Pharmacology of marihuana. Raven Press, New York, pp 93–113

    Google Scholar 

  • Wall ME, Sadler BM, Brine D, Taylor H, Perez-Reyes M (1983) Metabolism, disposition, and kinetics of delta-9-tetrahydrocannabinol in men and women. Clin Pharmacol Ther 34:352–363

    Article  PubMed  CAS  Google Scholar 

  • Watanabe K, Tanaka T, Yamamoto I, Yoshimura H (1988) Brain microsomal oxidation of delta-8-and delta-9-tetrahydrocannabinol. Biochem Biophys Res Commun 157:75–80

    Article  PubMed  CAS  Google Scholar 

  • Widman M, Agurell S, Ehrnebo M, Jones G (1974) Binding of (+) and (-)-delta1-tetrahydrocannabinols and (-)-7-hydroxy-delta1-tetrahydrocannabinol to blood cells and plasma proteins in man. J Pharm Pharmacol 26:914–916

    PubMed  CAS  Google Scholar 

  • Widman M, Nordqvist M, Dollery CT, Briant RH (1975) Metabolism of delta-1-tetrahydrocannabinol by the isolated perfused dog lung. Comparison with in vitro liver metabolism. J Pharm Pharmacol 27:842–848

    PubMed  CAS  Google Scholar 

  • Williams PL, Moffat AC (1980) Identification in human urine of delta-9-tetrahydrocannabinol-11-oic glucuronide: a tetrahydrocannabinol metabolite. J Pharm Pharmacol 32:445–448

    PubMed  CAS  Google Scholar 

  • Zajicek J, Fox P, Sanders H, Wright D, Vickery J, Nunn A, Thompson A (2003) Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet 362:1517–1526

    Article  PubMed  CAS  Google Scholar 

  • Zuardi AW, Shirakawa I, Finkelfarb E, Karniol IG (1982) Action of cannabidiol on the anxiety and other effects produced by delta-9-THC in normal subjects. Psychopharmacology (Berl) 76:245–250

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Chemistry and Drug Metabolism, Intramural Research Program, 5500 Nathan Shock Drive, Baltimore, MD, 21224, USA

    M. A. Huestis

Authors
  1. M. A. Huestis
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. School of Medical Sciences, Institute of Medical Science, University of Aberdeen, Foresterhill, Aberdeen, AB25 2ZD, Scotland, UK

    Roger G. Pertwee

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Springer-Verlag

About this chapter

Cite this chapter

Huestis, M.A. (2005). Pharmacokinetics and Metabolism of the Plant Cannabinoids, Δ 9-Tetrahydrocannibinol, Cannabidiol and Cannabinol. In: Pertwee, R.G. (eds) Cannabinoids. Handbook of Experimental Pharmacology, vol 168. Springer, Berlin, Heidelberg. https://doi.org/10.1007/3-540-26573-2_23

Download citation

Publish with us

Policies and ethics

Search

Navigation